A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
about
Inflammation and skeletal metastasisTwenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine.Cancer biomarker discovery: the entropic hallmark.A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.Molecular mechanisms of bone metastasis and associated muscle weakness.Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth.MicroRNAs in the control of metastatic bone disease.CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression.Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis.Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastasesInterleukin-17 Induces Expression of Chemokines and Cytokines in Prostatic Epithelial Cells but Does Not Stimulate Cell Growth In Vitro.Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer.Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.Monocyte chemoattractant protein-1/CCL2 produced by stromal cells promotes lung metastasis of 4T1 murine breast cancer cells.Expression of the inflammatory chemokines CCL2, CCL5 and CXCL2 and the receptors CCR1-3 and CXCR2 in T lymphocytes from mammary tumor-bearing mice.A MCP1 fusokine with CCR2-specific tumoricidal activityRoles of bone marrow cells in skeletal metastases: no longer bystandersPrognonstic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinomaCrosstalk between Tumor Cells and Macrophages in Stroma Renders Tumor Cells as the Primary Source of MCP-1/CCL2 in Lewis Lung Carcinoma.The IGR-CaP1 xenograft model recapitulates mixed osteolytic/blastic bone lesions observed in metastatic prostate cancerPrevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment.Drugs which inhibit osteoclast function suppress tumor growth through calcium reduction in bone.Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.Induction of Monocyte Chemoattractant Proteins in Macrophages via the Production of Granulocyte/Macrophage Colony-Stimulating Factor by Breast Cancer CellsBone marrow macrophages support prostate cancer growth in bone.The multifaceted actions of PTHrP in skeletal metastasisTargeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumorsCancer to bone: a fatal attraction.Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.Macrophages: Their Emerging Roles in Bone.Tumor-associated macrophages as incessant builders and destroyers of the cancer stroma.Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth.Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone.Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2.
P2860
Q28396089-B9A67597-3715-48DA-A35A-7AE0052C2FB8Q30416231-D73F50E0-1031-4915-A7AC-8E3762CCEC7BQ30496149-396AD316-1B8B-4D36-978A-046DEED0163CQ30504566-249FE3B0-1252-4FB0-B20D-7942A089DE45Q33415914-8C10454B-7FE6-49DB-B01E-9405C9F63361Q33758508-0579FE0E-8E84-4000-B408-08EB09358EB6Q33803085-8F9C3801-120C-44C2-BDFF-89DACE3B1C2EQ33821326-DD120322-3CE2-4123-9095-7B1412686166Q33897765-8970CF50-4A38-4FB0-B8C2-B310F37D2926Q34069836-6A367BBD-16DB-40CA-AFD6-38A6BDF47D49Q34107357-B8FCA80F-DCBF-4F71-AA86-9781F38FAEFCQ34132305-D1D2DAEF-F9C3-4B10-BB9F-7E6BFFA5650FQ34269107-F9426E03-4696-42F2-B339-543A47029F31Q34295041-B63E5ED1-B713-4F34-ABA9-7BB2A10F2DBCQ34309227-4F25CFBD-0F45-48C9-9234-1AE48F89B507Q34326476-8B6D4B15-5C42-4CB9-AF3A-68C6885EA7E8Q34626551-2DBFBFC3-4719-4E24-8573-8B339B37EBE0Q34634293-DB1E8114-00FE-4C25-9B2C-1DEEF939C378Q35166851-5EAD1C0C-E65C-4FF2-8E1E-E99A3E668D31Q35299025-5EB16227-99D3-4ACB-B69B-164F46B7B114Q35603122-76537D2B-9BA5-4E94-81D3-1E05C26AC136Q35681985-24BAD50A-A023-457E-BBF0-F877218F70E8Q35782923-9BD92630-736A-43C6-85DD-20AED2BB3FCDQ36062138-2E42E072-14F6-48A5-A7D0-0AE07166DB82Q36062163-8B2DD21B-04CA-436D-933C-F54E18C88A91Q36278275-9D7EB5C9-6A14-4D3E-AE58-B818C01ECD01Q36278280-4176FB3E-2798-465D-823B-F2CA2747720FQ36480181-C3110FFE-F0FF-4324-B490-F81DA58D0A38Q36546464-C6D7710D-99CD-4760-8AA2-223F8CE64821Q36593285-8A99C3D0-DBB5-4A10-88D2-51FDA1232C6EQ36869880-4181262E-2908-43B0-9FF3-A3E66E991420Q36884628-16CAEF04-CE47-4B09-BDDD-7D852BD04596Q36913771-4CFF7333-0B73-4B88-8FCD-AEDAB6BCF779Q36926240-2CC97327-67F3-4513-A3D6-960D50511669Q37148134-3BD73FF5-3FC3-45F9-BB9A-70F3A94B3277Q37222132-F1FB2579-2DDD-4A80-A24A-71263719CCEBQ37338567-4EA1A4CC-211E-4541-B82C-1CA446DAB3D3Q37431256-93B976C7-E81C-46F0-9BF9-4C70EA2DDEA8Q37626265-94CF356E-2D75-4E9E-A188-634B6CAA396DQ37651394-515919FD-0694-4319-BA8E-7C2DBC71E15E
P2860
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
@en
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
@nl
type
label
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
@en
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
@nl
prefLabel
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
@en
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.
@nl
P2093
P2860
P1433
P1476
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone
@en
P2093
Jinhui Liao
Laurie K McCauley
Linda A Snyder
Robert Loberg
P2860
P304
P356
10.1158/0008-5472.CAN-08-2164
P407
P577
2009-01-27T00:00:00Z